MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines

2000 ◽  
Vol 48 (10) ◽  
pp. 588-594 ◽  
Author(s):  
Bruce Acres ◽  
Vasso Apostolopoulos ◽  
Jean-Marc Balloul ◽  
Danny Wreschner ◽  
Pei-Xiang Xing ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Immune Responses ◽  
Human Muc1

scholarly journals Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection

Pathogens ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 940
Author(s):  
Theodor Chitlaru ◽  
Erez Bar-Haim ◽  
Liat Bar-On ◽  
Shahar Rotem ◽  
Hila Cohen ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Immune Responses ◽  
Post Infection ◽  
High Reproducibility ◽  
Cellular Immune Responses ◽  
Loss Of Weight ◽  
Transient Loss ◽  
Different Strains ◽  
Cellular Immune ◽  
Human Specific

HLA transgenic mice are instrumental for evaluation of human-specific immune responses to viral infection. Mice do not develop COVID-19 upon infection with SARS-CoV-2 due to the strict tropism of the virus to the human ACE2 receptor. The aim of the current study was the implementation of an adenovirus-mediated infection protocol for human ACE2 expression in HLA transgenic mice. Transient pulmonary expression of the human ACE2 receptor in these mice results in their sensitisation to SARS-CoV-2 infection, consequently providing a valuable animal model for COVID-19. Infection results in a transient loss in body weight starting 3 days post-infection, reaching 20–30% loss of weight at day 7 and full recovery at days 11–13 post-infection. The evolution of the disease revealed high reproducibility and very low variability among individual mice. The method was implemented in two different strains of HLA immunized mice. Infected animals developed strong protective humoral and cellular immune responses specific to the viral spike-protein, strictly depending on the adenovirus-mediated human ACE2 expression. Convalescent animals were protected against a subsequent re-infection with SARS-CoV-2, demonstrating that the model may be applied for assessment of efficacy of anti-viral immune responses.

Th2 Immune Responses in GATA-3-Transgenic Mice Infected with Heligmosomoides polygyrus

2003 ◽  
Vol 131 (Suppl. 1) ◽  
pp. 11-14 ◽  
Author(s):  
Naohiro Watanabe ◽  
Hidekazu Tamauchi ◽  
Hideyuki Ozawa ◽  
Mamoru Ito ◽  
Zoltan Ovary ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Immune Responses ◽  
Heligmosomoides Polygyrus

scholarly journals Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Kamal El Bissati ◽  
Ying Zhou ◽  
Sara M. Paulillo ◽  
Senthil K. Raman ◽  
Christopher P. Karch ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Immune Responses ◽  
Peptide Vaccine ◽  
New Paradigm ◽  
Mouse Splenocytes ◽  
Peptide Epitopes ◽  
Self Assembling ◽  
Tlr4 Ligand ◽  
Chimeric Polypeptide ◽  
Vaccine Approach

Abstract Fighting smart diseases requires smart vaccines. Novel ways to present protective immunogenic peptide epitopes to human immune systems are needed. Herein, we focus on Self Assembling Protein Nanoparticles (SAPNs) as scaffolds/platforms for vaccine delivery that produce strong immune responses against Toxoplasma gondii in HLA supermotif, transgenic mice. Herein, we present a useful platform to present peptides that elicit CD4+, CD8+ T and B cell immune responses in a core architecture, formed by flagellin, administered in combination with TLR4 ligand-emulsion (GLA-SE) adjuvant. We demonstrate protection of HLA-A*11:01, HLA-A*02:01, and HLA-B*07:02 mice against toxoplasmosis by (i) this novel chimeric polypeptide, containing epitopes that elicit CD8+ T cells, CD4+ T helper cells, and IgG2b antibodies, and (ii) adjuvant activation of innate immune TLR4 and TLR5 pathways. HLA-A*11:01, HLA-A*02:01, and HLA-B*07:02q11 transgenic mouse splenocytes with peptides demonstrated predicted genetic restrictions. This creates a new paradigm-shifting vaccine approach to prevent toxoplasmosis, extendable to other diseases.

scholarly journals DNA Immunization with Hepatitis C Virus (HCV) Polycistronic Genes or Immunization by HCV DNA Priming-Recombinant Canarypox Virus Boosting Induces Immune Responses and Protection from Recombinant HCV-Vaccinia Virus Infection in HLA-A2.1-Transgenic Mice

2003 ◽  
Vol 77 (1) ◽  
pp. 382-390 ◽  
Author(s):  
Preeti Pancholi ◽  
Marion Perkus ◽  
Nancy Tricoche ◽  
Qingyan Liu ◽  
Alfred M. Prince
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Transgenic Mice ◽  
Immune Responses ◽  
Vaccinia Virus ◽  
Target Cells ◽  
Dna Encoding ◽  
Recombinant Hcv ◽  
Hla A2.1 ◽  
Canarypox Virus

ABSTRACT We studied immune responses to hepatitis C virus (HCV) genes delivered as DNA encoding the entire HCV protein coding genome in two polycistronic plasmids encoding HCV capsid-E1-E2-NS2-NS3 and HCV NS3-NS4-NS5 in HLA-A2.1-transgenic mice. Immune responses to HCV DNA prime and recombinant canarypox virus boost were also studied with the above constructs. At 8 weeks after a canarypox virus boost, the DNA prime/canarypox virus boosting regimen induced potent cellular immune responses to HCV structural and nonstructural proteins on target cells expressing the HLA-A2.1 allele. High frequencies of gamma interferon-secreting cells, as detected by enzyme-linked immunospot assay, were obtained in response to several endogenously expressed HCV proteins. We also observed cytotoxic-T-lymphocyte reactivity in response to endogenously expressed HCV proteins in fresh spleen cells without in vitro expansion. Upon challenge with a recombinant vaccinia virus expressing HCV proteins at 2 months postimmunization, the HCV DNA prime/canarypox virus-immunized mice showed a complete reduction in vaccinia virus titers compared to HCV DNA prime/boost- and mock-immunized controls. Immune responses were still detectable 4 months after canarypox virus boost in immunized mice. Interestingly, at 10 months postimmunization (8 months after canarypox virus boost), the protection in HCV DNA prime/boost-immunized mice against recombinant HCV-vaccinia virus challenge was higher than that observed in HCV DNA prime/canarypox virus boost-immunized mice.

Human MUC1 Mucin: A Multifaceted Glycoprotein

2000 ◽  
Vol 15 (4) ◽  
pp. 343-356 ◽  
Author(s):  
S. von Mensdorff-Pouilly ◽  
F.G.M. Snijdewint ◽  
A.A. Verstraeten ◽  
R.H.M. Verheijen ◽  
P. Kenemans
Keyword(s):  
Immune System ◽  
Immune Responses ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Early Stage ◽  
Immune Recognition ◽  
Breast Cancer Patients ◽  
Phase I Clinical Trials ◽  
Muc1 Mucin ◽  
Human Muc1

Human MUC1 mucin, a membrane-bound glycoprotein, is a major component of the ductal cell surface of normal glandular cells. MUC1 is overexpressed and aberrantly glycosylated in carcinoma cells. The role MUC1 plays in cancer progression represents two sides of one coin: on the one hand, loss of polarity and overexpression of MUC1 in cancer cells interferes with cell adhesion and shields the tumor cell from immune recognition by the cellular arm of the immune system, thus favoring metastases; on the other hand, MUC1, in essence a self-antigen, is displaced and altered in malignancy and induces immune responses. Tumor-associated MUC1 has short carbohydrate sidechains and exposed epitopes on its peptide core; it gains access to the circulation and comes into contact with the immune system provoking humoral and cellular immune responses. Natural antibodies to MUC1 present in the circulation of cancer patients may be beneficial to the patient by restricting tumor growth and dissemination: early stage breast cancer patients with a humoral response to MUC1 have a better disease-specific survival. Several MUC1 peptide vaccines, differing in vectors, carrier proteins and adjuvants, have been tested in phase I clinical trials. They are capable of inducing predominantly humoral responses to the antigen, but evidence that these immune responses may be effective against the tumor in humans is still scarce.

Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with MUC1-C3d fusion protein

2007 ◽  
Vol 44 (1-3) ◽  
pp. 221
Author(s):  
Rieko Ohta ◽  
Masaki Imai ◽  
Chun He ◽  
Ted M. Ross ◽  
Stephen Tomlinson
Keyword(s):  
Transgenic Mice ◽  
Fusion Protein ◽  
Human Muc1
Sign in / Sign up

Export Citation Format

Share Document